Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2019 Nov 29;19(2):420–431. doi: 10.1158/1535-7163.MCT-19-0611

Figure 6.

Figure 6.

Sulforaphane (SFN) administration inhibits osteoclast formation in vivo. A, Representative hematoxylin and eosin (H&E)-stained sections (upper panel) and tartrate-resistant acid phosphatase positive (TRAP+) osteoclasts (lower panel) at ×5 objective magnification from control- and SFN-treated mice [dotted circles (Tu) indicate breast cancer cells in bone]. B, Quantitation of TRAP+ osteoclast number per field of bones. Results shown are mean ± SD (n=8). Statistical significance of difference was analyzed by unpaired Student’s t test). Quantitation of plasma levels of cathepsin K (C), receptor activator of nuclear factor κB ligand (RANKL, D), and interleukin-8 (IL8, E) from control- and SFN-treated mice. Results shown are mean ± SD (n=6–8). Statistical significance of difference was analyzed by unpaired Student t test (n = 7–8 for control and n = 6 for SFN group).